Synthetic chromatin engineering for STAT1 reactivation toward restoring cisplatin sensitivity in breast cancer

DR3 synthetic chromatin engineering reactivates STAT1 in cisplatin-resistant MDA-MB-231 TNBC cells, restoring cisplatin sensitivity via H2B ubiquitination–linked chromatin remodeling.

• Why it matters: Cisplatin-resistant breast cancers show suppressed transcription factor activity and altered chromatin accessibility, but strategies to reactivate key factors like STAT1 are limited.
• What they did: Integrative in silico work and cell validation showed reduced STAT1 expression/activity with defective nuclear translocation in resistant TNBC cells; DR3, a PHF6-derived regulator, was delivered to enhance STAT1 nuclear localization and transcription through histone H2B ubiquitination, assessed by CUT&RUN.
• The result: DR3 induced STAT1-associated inflammatory and tumor-suppressive miRNA programs, promoted non-canonical S727-dependent STAT1 activation, increased accessibility at STAT1 regulatory regions, upregulated HIPK2, strengthened intrinsic DNA damage response, and restored cisplatin sensitivity in resistant breast tumors in vivo.

AI summary of the abstract · may contain errors · not medical advice · read the paper.